{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:27:46Z","timestamp":1777498066267,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UNC Lineberger Comprehensive Cancer Center; University Cancer Research Fund of North Carolina","award":["OG22873776"],"award-info":[{"award-number":["OG22873776"]}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["OGUNC1202, TREND21686258, SAC210102"],"award-info":[{"award-number":["OGUNC1202, TREND21686258, SAC210102"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["RCMI U54MD012392 and R01MD017405"],"award-info":[{"award-number":["RCMI U54MD012392 and R01MD017405"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA253450"],"award-info":[{"award-number":["R01CA253450"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute Specialized Program of Research Excellence (SPORE) in Breast Cancer","award":["NIH\/NCI P50-CA058223"],"award-info":[{"award-number":["NIH\/NCI P50-CA058223"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["HEI-23-003"],"award-info":[{"award-number":["HEI-23-003"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT94252310235"],"award-info":[{"award-number":["HT94252310235"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Inflammatory breast cancer (IBC) has been hypothesized to represent a distinct molecular subtype. However, few IBC-specific gene expression patterns have been identified, and previous genomic studies of IBC have been small with limited information on social determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We identified 153 IBC cases in the Carolina Breast Cancer Study (total\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20094,739). RNA expression was measured on the NanoString platform (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200974 IBC, 2,696 non-IBC) and used to determine molecular subtypes, including PAM50, immune, homologous recombination deficiency (HRD), and P53 status. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of associations between IBC and patient demographic, molecular, and social characteristics using logistic regression, and compared differences in gene expression using ANOVA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Women with IBC were associated with Black and under 50 compared to non-IBC. IBC was associated with rural address (OR\u2009=\u20091.53) and poverty (OR\u2009=\u20091.61). Molecularly, IBC was associated with HER2-enriched (OR\u2009=\u20096.14), Luminal B (OR\u2009=\u20092.90), P53 Mutant-like (OR\u2009=\u20091.79), and high HRD (OR\u2009=\u20091.90). Neither adiposity nor immune subtype was significantly associated with IBC. Only six of 219 genes measured were significantly differentially expressed between IBC and non-IBC, including HER2-related (ERBB2, FGFR4, GRB7) and P53-related genes (BTG2, LOC400043, MAP2K4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07884-3","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:03:58Z","timestamp":1769090638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study"],"prefix":"10.1007","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1183-9939","authenticated-orcid":false,"given":"Qichen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Van Alsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob U.","family":"Onyenwoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-6624","authenticated-orcid":false,"given":"Melissa A.","family":"Troester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-4630","authenticated-orcid":false,"given":"Kevin P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"7884_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ajog.2021.04.217","volume":"225","author":"RH Hester","year":"2021","unstructured":"Hester RH, Hortobagyi GN, Lim B (2021) Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol 225:392\u2013396. https:\/\/doi.org\/10.1016\/j.ajog.2021.04.217","journal-title":"Am J Obstet Gynecol"},{"key":"7884_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3322\/caac.20082","volume":"60","author":"FM Robertson","year":"2010","unstructured":"Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351\u2013375. https:\/\/doi.org\/10.3322\/caac.20082","journal-title":"CA Cancer J Clin"},{"key":"7884_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515\u2013523. https:\/\/doi.org\/10.1093\/annonc\/mdq345","journal-title":"Ann Oncol"},{"key":"7884_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","volume":"192","author":"R Jagsi","year":"2022","unstructured":"Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, Lang JE, Alpaugh M, Williams KP, Vaught D, Smith A, Smith K, Miller KD, Susan G (2022) Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat 192:235\u2013243. https:\/\/doi.org\/10.1007\/s10549-021-06434-x","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/bjc.2015.115","volume":"112","author":"D Rea","year":"2015","unstructured":"Rea D, Francis A, Hanby AM, Speirs V, Rakha E, Shaaban A, Chan S, Vinnicombe S, Ellis IO, Martin SG, Jones LJ, Berditchevski F (2015) Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer 112:1613\u20131615. https:\/\/doi.org\/10.1038\/bjc.2015.115","journal-title":"Br J Cancer"},{"key":"7884_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5281\/zenodo.10048312","volume":"35","author":"A-F Mentis","year":"2023","unstructured":"Mentis A-F, Zervoudis S, Papadopoulos G, Spanopoulos C, Balafouta M, Tsakiris G, Bothou A, Jim\u00e9nez J, Garcia I, Tsikouras P, Iatrakis G, Nikolettos N (2023) Case series of inflammatory breast cancer in two Greek hospitals: our experience and critical appraisal. Rev Clin Pharmacol Pharmacokinet Int Ed 35:95\u2013102. https:\/\/doi.org\/10.5281\/zenodo.10048312","journal-title":"Rev Clin Pharmacol Pharmacokinet Int Ed"},{"key":"7884_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11912-019-0842-y","volume":"21","author":"JM Rosenbluth","year":"2019","unstructured":"Rosenbluth JM, Overmoyer BA (2019) Inflammatory breast cancer: a separate entity. Curr Oncol Rep 21:86. https:\/\/doi.org\/10.1007\/s11912-019-0842-y","journal-title":"Curr Oncol Rep"},{"key":"7884_CR8","volume-title":"StatPearls","author":"V Chippa","year":"2025","unstructured":"Chippa V, Barazi H (2025) Inflammatory Breast Cancer. StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"7884_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4754827","volume":"2017","author":"RJ Morrow","year":"2017","unstructured":"Morrow RJ, Etemadi N, Yeo B, Ernst M (2017) Challenging a misnomer? The role of inflammatory pathways in inflammatory breast cancer. Mediators Inflamm 2017:4754827. https:\/\/doi.org\/10.1155\/2017\/4754827","journal-title":"Mediators Inflamm"},{"key":"7884_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.ircmb.2023.10.006","volume":"384","author":"C Rypens","year":"2024","unstructured":"Rypens C, Van Berckelaer C, Berditchevski F, van Dam P, Van Laere S (2024) Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models. Int Rev Cell Mol Biol 384:77\u2013112. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.10.006","journal-title":"Int Rev Cell Mol Biol"},{"key":"7884_CR11","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-12-2549","volume":"19","author":"SJ Van Laere","year":"2013","unstructured":"Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F (2013) Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res 19:4685\u20134696. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2549","journal-title":"Clin Cancer Res"},{"key":"7884_CR12","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.1158\/0008-5472.CAN-04-2696","volume":"64","author":"F Bertucci","year":"2004","unstructured":"Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64:8558\u20138565. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2696","journal-title":"Cancer Res"},{"key":"7884_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10549-013-2501-6","volume":"138","author":"WA Woodward","year":"2013","unstructured":"Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S-I, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT (2013) Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat 138:761\u2013772. https:\/\/doi.org\/10.1007\/s10549-013-2501-6","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-005-5157-z","volume":"93","author":"S Van Laere","year":"2005","unstructured":"Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY (2005) Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 93:237\u2013246. https:\/\/doi.org\/10.1007\/s10549-005-5157-z","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101026","volume":"14","author":"P Chakraborty","year":"2021","unstructured":"Chakraborty P, George JT, Woodward WA, Levine H, Jolly MK (2021) Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum. Transl Oncol 14:101026. https:\/\/doi.org\/10.1016\/j.tranon.2021.101026","journal-title":"Transl Oncol"},{"key":"7884_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222336","volume":"14","author":"Y Funakoshi","year":"2019","unstructured":"Funakoshi Y, Wang Y, Semba T, Masuda H, Hout D, Ueno NT, Wang X (2019) Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS One 14:e0222336. https:\/\/doi.org\/10.1371\/journal.pone.0222336","journal-title":"PLoS One"},{"key":"7884_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2014.09.003","volume":"93","author":"DJP van Uden","year":"2015","unstructured":"van Uden DJP, van Laarhoven HWM, Westenberg AH, de Wilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol 93:116\u2013126. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.09.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"7884_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10552-015-0712-3","volume":"27","author":"RL Atkinson","year":"2016","unstructured":"Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM (2016) Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control 27:359\u2013366. https:\/\/doi.org\/10.1007\/s10552-015-0712-3","journal-title":"Cancer Causes Control"},{"key":"7884_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1023\/B:CACO.0000024222.61114.18","volume":"15","author":"PA Wingo","year":"2004","unstructured":"Wingo PA, Jamison PM, Young JL, Gargiullo P (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15:321\u2013328. https:\/\/doi.org\/10.1023\/B:CACO.0000024222.61114.18","journal-title":"Cancer Causes Control"},{"key":"7884_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","volume":"97","author":"KW Hance","year":"2005","unstructured":"Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966\u2013975. https:\/\/doi.org\/10.1093\/jnci\/dji172","journal-title":"J Natl Cancer Inst"},{"key":"7884_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1245\/s10434-013-3439-y","volume":"21","author":"B Goldner","year":"2014","unstructured":"Goldner B, Behrendt CE, Schoellhammer HF, Lee B, Chen SL (2014) Incidence of inflammatory breast cancer in women, 1992\u20132009, United States. Ann Surg Oncol 21:1267\u20131270. https:\/\/doi.org\/10.1245\/s10434-013-3439-y","journal-title":"Ann Surg Oncol"},{"key":"7884_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00694745","volume":"35","author":"B Newman","year":"1995","unstructured":"Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET (1995) The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35:51\u201360. https:\/\/doi.org\/10.1007\/BF00694745","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","volume":"109","author":"RC Millikan","year":"2008","unstructured":"Millikan RC, Newman B, Tse C-K, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123\u2013139. https:\/\/doi.org\/10.1007\/s10549-007-9632-6","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djy136","volume":"111","author":"SB Wheeler","year":"2019","unstructured":"Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L, Olshan A, Tse CK, Bell ME, Weinberger M, Reeder-Hayes KE (2019) Endocrine therapy nonadherence and discontinuation in Black and White women. J Natl Cancer Inst 111:498\u2013508. https:\/\/doi.org\/10.1093\/jnci\/djy136","journal-title":"J Natl Cancer Inst"},{"key":"7884_CR25","unstructured":"World Health Organization (2011) Waist circumference and waist-hip ratio\u202f: report of a WHO expert consultation, Geneva, 8\u201311 December 2008"},{"key":"7884_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1055-9965.EPI-15-0874","volume":"25","author":"EH Allott","year":"2016","unstructured":"Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O\u2019Connor S, Tse C-K, Bell MB, Hu Z, Li Y, Kirk EL, Bethea TN, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA (2016) Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 25:470\u2013478. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0874","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"7884_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Buuren","year":"2011","unstructured":"Buuren S, Groothuis-Oudshoorn K (2011) mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","journal-title":"J Stat Softw"},{"key":"7884_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.bjc.6606078","volume":"104","author":"AMG Ali","year":"2011","unstructured":"Ali AMG, Dawson S-J, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD (2011) Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 104:693\u2013699. https:\/\/doi.org\/10.1038\/sj.bjc.6606078","journal-title":"Br J Cancer"},{"key":"7884_CR29","unstructured":"Poverty Guidelines. In: ASPE. http:\/\/aspe.hhs.gov\/topics\/poverty-economic-mobility\/poverty-guidelines. Accessed 19 Aug 2025"},{"key":"7884_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa163","volume":"22","author":"A Bhattacharya","year":"2021","unstructured":"Bhattacharya A, Hamilton AM, Furberg H, Pietzak E, Purdue MP, Troester MA, Hoadley KA, Love MI (2021) An approach for normalization and quality control for NanoString RNA expression data. Brief Bioinform 22:bbaa163. https:\/\/doi.org\/10.1093\/bib\/bbaa163","journal-title":"Brief Bioinform"},{"key":"7884_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1055-9965.EPI-21-1312","volume":"31","author":"AM Hamilton","year":"2022","unstructured":"Hamilton AM, Hurson AN, Olsson LT, Walens A, Nsonwu-Farley J, Kirk EL, Abdou Y, Downs-Canner SM, Serody JS, Perou CM, Calhoun BC, Troester MA, Hoadley KA (2022) The landscape of immune microenvironments in racially diverse breast cancer patients. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 31:1341\u20131350. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-1312","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"7884_CR32","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1158\/1055-9965.EPI-22-0590","volume":"31","author":"A Walens","year":"2022","unstructured":"Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA (2022) RNA-based classification of homologous recombination deficiency in racially diverse patients with breast cancer. Cancer Epidemiol Biomarkers Prev 31:2136\u20132147. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0590","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7884_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00137","volume":"8","author":"SC Van Alsten","year":"2024","unstructured":"Van Alsten SC, Vohra SN, Ivory JM, Hamilton AM, Gao X, Kirk EL, Butler EN, Earp HS, Reeder-Hayes KE, Hoadley KA, Carey LA, Troester MA (2024) Differences in 21-gene and PAM50 recurrence scores in younger and Black women with breast cancer. JCO Precis Oncol 8:e2400137. https:\/\/doi.org\/10.1200\/PO.24.00137","journal-title":"JCO Precis Oncol"},{"key":"7884_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso D, Ngai J, Speed TP, Dudoit S (2014) Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol 32:896\u2013902. https:\/\/doi.org\/10.1038\/nbt.2931","journal-title":"Nat Biotechnol"},{"key":"7884_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41523-018-0067-5","volume":"4","author":"LA Williams","year":"2018","unstructured":"Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA (2018) TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. NPJ Breast Cancer 4:13. https:\/\/doi.org\/10.1038\/s41523-018-0067-5","journal-title":"NPJ Breast Cancer"},{"key":"7884_CR36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol 27:1160\u20131167. https:\/\/doi.org\/10.1200\/JCO.2008.18.1370","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7884_CR37","volume-title":"Machine learning with R: discover how to build machine learning algorithms, prepare data, and dig deep into data prediction techniques with R, second edition","author":"B Lantz","year":"2015","unstructured":"Lantz B (2015) Machine learning with R: discover how to build machine learning algorithms, prepare data, and dig deep into data prediction techniques with R, second edition, 2nd edn. Packt Publishing, Place of publication not identified","edition":"2"},{"key":"7884_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jnci\/djx135","volume":"110","author":"MA Troester","year":"2018","unstructured":"Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse C-K, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM (2018) Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:176\u2013182. https:\/\/doi.org\/10.1093\/jnci\/djx135","journal-title":"J Natl Cancer Inst"},{"key":"7884_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1471-2407-6-276","volume":"6","author":"MA Troester","year":"2006","unstructured":"Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6:276. https:\/\/doi.org\/10.1186\/1471-2407-6-276","journal-title":"BMC Cancer"},{"key":"7884_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1055-9965.EPI-21-0661","volume":"31","author":"AN Hurson","year":"2022","unstructured":"Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA (2022) TP53 pathway function, estrogen receptor status, and breast cancer risk factors in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 31:124\u2013131. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-0661","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7884_CR41","unstructured":"(2023) R: The R Project for Statistical Computing"},{"key":"7884_CR42","unstructured":"(2023) SAS Help Center: SAS\/STAT User\u2019s Guide"},{"key":"7884_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10549-020-05785-1","volume":"183","author":"C Schairer","year":"2020","unstructured":"Schairer C, Laurent CA, Moy LM, Gierach GL, Caporaso NE, Pfeiffer RM, Kushi LH (2020) Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study. Breast Cancer Res Treat 183:467\u2013478. https:\/\/doi.org\/10.1007\/s10549-020-05785-1","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR44","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/jnci\/djt206","volume":"105","author":"C Schairer","year":"2013","unstructured":"Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DSM, Kerlikowske K, Onega TL, Anderson WF, Miglioretti DL (2013) Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst 105:1373\u20131384. https:\/\/doi.org\/10.1093\/jnci\/djt206","journal-title":"J Natl Cancer Inst"},{"key":"7884_CR45","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1200\/JCO.1998.16.12.3731","volume":"16","author":"S Chang","year":"1998","unstructured":"Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol Off J Am Soc Clin Oncol 16:3731\u20133735. https:\/\/doi.org\/10.1200\/JCO.1998.16.12.3731","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7884_CR46","first-page":"1324","volume":"35","author":"J Zhou","year":"2014","unstructured":"Zhou J, Yan Y, Guo L, Ou H, Hai J, Zhang C, Wu Z, Tang L (2014) Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer. Saudi Med J 35:1324\u20131330","journal-title":"Saudi Med J"},{"key":"7884_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5152\/ejbh.2018.4170","volume":"14","author":"B \u00c7akar","year":"2018","unstructured":"\u00c7akar B, S\u00fcrmeli Z, \u00d6ner PG, Yelim ES, Karabulut B, Uslu R (2018) The impact of subtype distribution in inflammatory breast cancer outcome. Eur J Breast Health 14:211\u2013217. https:\/\/doi.org\/10.5152\/ejbh.2018.4170","journal-title":"Eur J Breast Health"},{"key":"7884_CR48","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn H-J, Panel members (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206\u20132223. https:\/\/doi.org\/10.1093\/annonc\/mdt303","journal-title":"Ann Oncol"},{"issue":"6","key":"7884_CR49","doi-asserted-by":"publisher","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","volume":"24","author":"E Senkus","year":"2013","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F, ESMO Guidelines Working Group (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 24(6):vi7-23. https:\/\/doi.org\/10.1093\/annonc\/mdt284","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7884_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41523-025-00764-5","volume":"11","author":"JJL van Geel","year":"2025","unstructured":"van Geel JJL, Jongbloed EM, Moustaquim J, van der Schoor G, van Leeuwen-Stok AE, Smid M, van Deurzen CHM, Wilting SM, Wesseling J, Sonke GS, Martens JWM, Schr\u00f6der CP (2025) Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study. NPJ Breast Cancer 11:48. https:\/\/doi.org\/10.1038\/s41523-025-00764-5","journal-title":"NPJ Breast Cancer"},{"key":"7884_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2407-8-28","volume":"8","author":"A Ben Hamida","year":"2008","unstructured":"Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D, Jacquemier J (2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8:28. https:\/\/doi.org\/10.1186\/1471-2407-8-28","journal-title":"BMC Cancer"},{"key":"7884_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-015-3592-z","volume":"154","author":"JS Ross","year":"2015","unstructured":"Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M (2015) Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat 154:155\u2013162. https:\/\/doi.org\/10.1007\/s10549-015-3592-z","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-017-4165-0","volume":"163","author":"N Matsuda","year":"2017","unstructured":"Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT (2017) Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 163:263\u2013272. https:\/\/doi.org\/10.1007\/s10549-017-4165-0","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR54","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.1038\/sj.onc.1205932","volume":"21","author":"E Turpin","year":"2002","unstructured":"Turpin E, Bi\u00e8che I, Bertheau P, Plassa L-F, Lerebours F, de Roquancourt A, Olivi M, Espi\u00e9 M, Marty M, Lidereau R, Vidaud M, de Th\u00e9 H (2002) Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21:7593\u20137597. https:\/\/doi.org\/10.1038\/sj.onc.1205932","journal-title":"Oncogene"},{"key":"7884_CR55","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1158\/1078-0432.CCR-24-2081","volume":"31","author":"N Priedigkeit","year":"2025","unstructured":"Priedigkeit N, Harrison B, Shue R, Hughes ME, Li Y, Lebr\u00f3n-Torres A, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney A-M, Grant L, Mohammed-Abreu A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack AD, Lin NU, Lynce F (2025) Clinicogenomic characterization of inflammatory breast cancer. Clin Cancer Res 31:3072\u20133083. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2081","journal-title":"Clin Cancer Res"},{"key":"7884_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05198-4","volume":"22","author":"F Bertucci","year":"2024","unstructured":"Bertucci F, Lerebours F, Ceccarelli M, Guille A, Syed N, Finetti P, Ad\u00e9la\u00efde J, Van Laere S, Goncalves A, Viens P, Birnbaum D, Mamessier E, Callens C, Bedognetti D (2024) Mutational landscape of inflammatory breast cancer. J Transl Med 22:374. https:\/\/doi.org\/10.1186\/s12967-024-05198-4","journal-title":"J Transl Med"},{"key":"7884_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1929724","volume":"10","author":"F Bertucci","year":"2021","unstructured":"Bertucci F, Boudin L, Finetti P, Van Berckelaer C, Van Dam P, Dirix L, Viens P, Gon\u00e7alves A, Ueno NT, Van Laere S, Birnbaum D, Mamessier E (2021) Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. Oncoimmunology 10:1929724. https:\/\/doi.org\/10.1080\/2162402X.2021.1929724","journal-title":"Oncoimmunology"},{"key":"7884_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7983","volume":"8","author":"X Wang","year":"2022","unstructured":"Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT (2022) EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv 8:eabn7983. https:\/\/doi.org\/10.1126\/sciadv.abn7983","journal-title":"Sci Adv"},{"key":"7884_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000524549","volume":"90","author":"NM Badr","year":"2023","unstructured":"Badr NM, McMurray JL, Danial I, Hayward S, Asaad NY, Abd El-Wahed MM, Abdou AG, Serag El-Dien MM, Sharma N, Horimoto Y, Sircar T, Vidya R, Hoar F, Rea D, Jones JL, Stevens A, Spooner D, Merard R, Lewis P, Hunter KJ, Berditchevski F, Shaaban AM (2023) Characterization of the immune microenvironment in inflammatory breast cancer using multiplex immunofluorescence. Pathobiol J Immunopathol Mol Cell Biol 90:31\u201343. https:\/\/doi.org\/10.1159\/000524549","journal-title":"Pathobiol J Immunopathol Mol Cell Biol"},{"key":"7884_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-021-06391-5","volume":"190","author":"H Arias-Pulido","year":"2021","unstructured":"Arias-Pulido H, Cimino-Mathews AM, Chaher N, Qualls CR, Joste N, Colpaert C, Marotti JD, Chamberlin MD, Foisey MG, Prossnitz ER, Emens LA, Fiering S (2021) Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. Breast Cancer Res Treat 190:477\u2013489. https:\/\/doi.org\/10.1007\/s10549-021-06391-5","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13058-020-01371-x","volume":"22","author":"SV Fernandez","year":"2020","unstructured":"Fernandez SV, MacFarlane AW, Jillab M, Arisi MF, Yearley J, Annamalai L, Gong Y, Cai KQ, Alpaugh RK, Cristofanilli M, Campbell KS (2020) Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast Cancer Res 22:134. https:\/\/doi.org\/10.1186\/s13058-020-01371-x","journal-title":"Breast Cancer Res"},{"key":"7884_CR62","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdl145","volume":"17","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol Off J Eur Soc Med Oncol 17:1497\u20131503. https:\/\/doi.org\/10.1093\/annonc\/mdl145","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7884_CR63","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1200\/JCO.2006.10.3754","volume":"25","author":"SH Ahn","year":"2007","unstructured":"Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko S-S, Han W, Korean Breast Cancer Society (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea\u2013a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360\u20132368. https:\/\/doi.org\/10.1200\/JCO.2006.10.3754","journal-title":"J Clin Oncol"},{"key":"7884_CR64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","volume":"36","author":"CK Anders","year":"2009","unstructured":"Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36:237\u2013249. https:\/\/doi.org\/10.1053\/j.seminoncol.2009.03.001","journal-title":"Semin Oncol"},{"key":"7884_CR65","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.surg.2021.08.061","volume":"171","author":"T Relation","year":"2022","unstructured":"Relation T, Li Y, Fisher JL, Tsung A, Oppong B, Eskander MF, Obeng-Gyasi S (2022) Inflammatory breast cancer, trimodal treatment, and mortality: does where you live matter? Surgery 171:687\u2013692. https:\/\/doi.org\/10.1016\/j.surg.2021.08.061","journal-title":"Surgery"},{"key":"7884_CR66","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/tbj.14283","volume":"27","author":"A Lehrberg","year":"2021","unstructured":"Lehrberg A, Sebai M, Finn D, Lee D, Karabon P, Kiran S, Dekhne N (2021) Trends, survival outcomes, and predictors of nonadherence to mastectomy guidelines for nonmetastatic inflammatory breast cancer. Breast J 27:753\u2013760. https:\/\/doi.org\/10.1111\/tbj.14283","journal-title":"Breast J"},{"key":"7884_CR67","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-018-4715-0","volume":"169","author":"A Weiss","year":"2018","unstructured":"Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G (2018) Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat 169:615\u2013623. https:\/\/doi.org\/10.1007\/s10549-018-4715-0","journal-title":"Breast Cancer Res Treat"},{"key":"7884_CR68","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/ijerph14040404","volume":"14","author":"L Scott","year":"2017","unstructured":"Scott L, Mobley LR, Il\u2019yasova D (2017) Geospatial analysis of inflammatory breast cancer and associated community characteristics in the United States. Int J Environ Res Public Health 14:404. https:\/\/doi.org\/10.3390\/ijerph14040404","journal-title":"Int J Environ Res Public Health"},{"key":"7884_CR69","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7574946","volume":"2017","author":"RA Denu","year":"2017","unstructured":"Denu RA, Hampton JM, Currey A, Anderson RT, Cress RD, Fleming ST, Lipscomb J, Wu X-C, Wilson JF, Trentham-Dietz A (2017) Racial and socioeconomic disparities are more pronounced in inflammatory breast cancer than other breast cancers. J Cancer Epidemiol 2017:7574946. https:\/\/doi.org\/10.1155\/2017\/7574946","journal-title":"J Cancer Epidemiol"},{"key":"7884_CR70","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1245\/s10434-022-12237-1","volume":"29","author":"LM Drapalik","year":"2022","unstructured":"Drapalik LM, Hue JJ, Simpson A, Freyvogel M, Rock L, Shenk RR, Amin AL, Miller ME (2022) Guideline-consistent treatment for inflammatory breast cancer provides associated survival benefit independent of age. Ann Surg Oncol 29:6469\u20136479. https:\/\/doi.org\/10.1245\/s10434-022-12237-1","journal-title":"Ann Surg Oncol"},{"key":"7884_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2020.08.014","volume":"29","author":"S Chainitikun","year":"2021","unstructured":"Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT (2021) Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 29:1\u201312. https:\/\/doi.org\/10.1016\/j.jare.2020.08.014","journal-title":"J Adv Res"},{"key":"7884_CR72","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5483\/BMBRep.2022.55.8.092","volume":"55","author":"SH Kim","year":"2022","unstructured":"Kim SH, Jung IR, Hwang SS (2022) Emerging role of anti-proliferative protein BTG1 and BTG2. BMB Rep 55:380\u2013388. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.8.092","journal-title":"BMB Rep"},{"key":"7884_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13058-016-0673-9","volume":"18","author":"E Powell","year":"2016","unstructured":"Powell E, Shao J, Yuan Y, Chen H-C, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do K-A, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H (2016) p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18:13. https:\/\/doi.org\/10.1186\/s13058-016-0673-9","journal-title":"Breast Cancer Res"},{"key":"7884_CR74","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/jnci\/djaf088","volume":"117","author":"F Lynce","year":"2025","unstructured":"Lynce F, Niman SM, Kai M, Ryan S, Troll E, Li L, Miller KD, Jagsi R, Mason G, Overmoyer BA, Le-Petross HTC, Nakhlis F, Krishnamurthy S, Harrison BT, Sun SX, Yeh ED, Bellon JR, Warren LE, Stauder MC, Regan MM, Woodward WA (2025) Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score. J Natl Cancer Inst 117:1583\u20131592. https:\/\/doi.org\/10.1093\/jnci\/djaf088","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07884-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:09:31Z","timestamp":1770034171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07884-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7884"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07884-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of North Carolina, Chapel Hill has a license of intellectual property interest in GeneCentric Diagnostics and BioClassifier, LLC, which may be used in this study. The University of North Carolina, Chapel Hill may benefit from this interest that is\/are related to this research. The terms of this arrangement have been reviewed and approved by the University of North Carolina, Chapel Hill Conflict of Interest Program in accordance with its conflict of interest policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the University of North Carolina Institutional Review Board in accordance with U.S. Common Rule. This study complied with relevant ethical regulations, including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained at enrollment for conducting interviews, collecting tumor samples, and accessing pathology reports and medical records previously collected through the CBCS. This study involves secondary analysis from de-identified CBCS data and is strictly observational, requiring no interaction with study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"61"}}